Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 5
2009 2
2010 1
2019 1
2020 2
2021 1
2022 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.
Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, Musso M, Giebel S, Uzay A, Langmuir P, Hollaender N, Gowda M, Stefanelli T, Lee SJ, Teshima T, Locatelli F; REACH3 Investigators. Zeiser R, et al. Among authors: stefanelli t. N Engl J Med. 2021 Jul 15;385(3):228-238. doi: 10.1056/NEJMoa2033122. N Engl J Med. 2021. PMID: 34260836 Clinical Trial.
A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis.
Harrison C, Heidel FH, Vannucchi AM, Kiladjian JJ, Hayat A, Passamonti F, Conneally E, Kindler T, Martino B, Lipka DB, Stefanelli T, Roussou P, Germano D, Ewan J, Ribrag V. Harrison C, et al. Among authors: stefanelli t. Hemasphere. 2022 Aug 2;6(8):e757. doi: 10.1097/HS9.0000000000000757. eCollection 2022 Aug. Hemasphere. 2022. PMID: 35935608 Free PMC article. No abstract available.
Cytapheresis in inflammatory bowel diseases: current evidence and perspectives.
Danese S, Angelucci E, Stefanelli T, Omodei P, Luigiano C, Finazzi S, Pagano N, Repici A, Vecchi M, Malesci A. Danese S, et al. Among authors: stefanelli t. Digestion. 2008;77(2):96-107. doi: 10.1159/000122473. Epub 2008 Apr 1. Digestion. 2008. PMID: 18382085 Free article. Review.
A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor.
Pantaleo MA, Heinrich MC, Italiano A, Valverde C, Schöffski P, Grignani G, Reyners AKL, Bauer S, Reichardt P, Stark D, Berhanu G, Brandt U, Stefanelli T, Gelderblom H. Pantaleo MA, et al. Among authors: stefanelli t. BMC Cancer. 2022 May 6;22(1):511. doi: 10.1186/s12885-022-09610-4. BMC Cancer. 2022. PMID: 35524239 Free PMC article. Clinical Trial.
Five-year survival follow-up of a phase III randomised trial comparing ofatumumab versus physicians' choice for bulky fludarabine-refractory chronic lymphocytic leukaemia: a short report.
Miklos U, Strugov V, Lewerin C, Grosicki S, Mazur G, Steurer M, Montillo M, Kryachok I, Middeke JM, Rekhtman G, Stefanelli T, Vincent G, Govindaraju S, Österborg A. Miklos U, et al. Among authors: stefanelli t. Br J Haematol. 2020 May;189(4):689-693. doi: 10.1111/bjh.16429. Epub 2020 Jan 28. Br J Haematol. 2020. PMID: 31994178 Free article. Clinical Trial.
A 5-year follow-up to evaluate the efficacy and safety of ofatumumab added to fludarabine and cyclophosphamide in patients with relapsed chronic lymphocytic leukemia: final analysis of the COMPLEMENT 2 trial.
Grosicki S, Lech-Maranda E, Govind Babu K, Rybka J, Litvinskaya E, Loscertales J, Kriachok I, Kłoczko J, Rekhtman G, Homenda W, Blonski J, Stefanelli T, Vincent G, Banerjee H, Robak T. Grosicki S, et al. Among authors: stefanelli t. Leuk Lymphoma. 2020 Jul;61(7):1748-1751. doi: 10.1080/10428194.2020.1732960. Epub 2020 Feb 28. Leuk Lymphoma. 2020. PMID: 32107948 No abstract available.
15 results